INSIGHTS

s Q4 begins, biopharma strategic planning takes center stage. What was once a quarter for cleanup is now a critical reset period for 2026. Investor pressure, pricing reform, transparency mandates, and tariff risks are reshaping commercial priorities. For leadership teams, the challenge is clear: recalibrate forecasts, refine launch plans, and align strategy to today’s realities before competitors pull ahead.

Patient journey mapping has transformed how life sciences companies understand and serve patients—but most maps miss a crucial voice: the caregiver. By expanding mapping to capture real-time, diverse patient experiences and integrating caregiver perspectives, companies can design more relevant trials, value-based products, and compelling launch narratives. Including those who guide patients through care not only humanizes development but drives adherence, satisfaction, and co

Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.

Phase 3 isn’t just a regulatory milestone—it’s a product’s pseudo launch. In today’s competitive biopharma landscape, success depends on building product differentiation early, not after approval. The design of late-stage trials shapes labeling, messaging, and market access. By embedding differentiation into clinical strategy, companies can turn regulatory readiness into true commercial advantage.

Psychiatry is emerging as the most capital-efficient segment in CNS, attracting major biopharma investment with late-phase assets, validated endpoints, and scalable commercial models. As neurodegeneration remains high-risk, psychiatry offers near-term ROI and strategic fit across the value chain.

Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.